<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05702034</url>
  </required_header>
  <id_info>
    <org_study_id>CR109231</org_study_id>
    <secondary_id>70033093STR3001</secondary_id>
    <secondary_id>2022-501176-26-00</secondary_id>
    <nct_id>NCT05702034</nct_id>
  </id_info>
  <brief_title>A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE</brief_title>
  <acronym>LIBREXIA-STROK</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol Myers Squibb Company (BMS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether milvexian compared to placebo reduce the&#xD;
      risk of recurrent ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Occurrence of Ischemic Stroke</measure>
    <time_frame>Up to global targeted endpoint date (approximately 41 months)</time_frame>
    <description>Time to first occurrence of ischemic stroke will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of any Component of the Composite of Cardiovascular Death (CVD), Myocardial Infraction (MI), or Ischemic Stroke</measure>
    <time_frame>Up to global targeted endpoint date (approximately 41 months)</time_frame>
    <description>Time to first occurrence of any component of the composite of CVD, MI, or ischemic stroke will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Ischemic Stroke</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>Time to first occurrence of ischemic stroke in the first 90 days will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of any Component of Major Adverse Vascular Events (MAVE)</measure>
    <time_frame>Up to global targeted endpoint date (approximately 41 months)</time_frame>
    <description>Time to first occurrence of any component of MAVE will be reported. MAVE is a composite of (CVD), myocardial infarction (MI), ischemic stroke, major adverse limb events (MALE), symptomatic pulmonary embolism (PE) or deep vein thrombosis (DVT).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Ischemic Stroke; Ischemic Attack, Transient</condition>
  <arm_group>
    <arm_group_label>Milvexian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants after an acute ischemic stroke or high-risk transient ischemic attack (TIA) who are receiving antiplatelet therapy standard-of-care (SAPT [single antiplatelet therapy] or DAPT [dual antiplatelet therapy]) will receive milvexian orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants after an acute ischemic stroke or high-risk TIA who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) will receive placebo orally twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milvexian</intervention_name>
    <description>Milvexian will be administered orally.</description>
    <arm_group_label>Milvexian</arm_group_label>
    <other_name>JNJ-70033093, BMS-986177</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ischemic Stroke: a neurological deficit attributable to an acute brain infarction and&#xD;
             national institute of health stroke score scale (NIHSS) score less than or equal to&#xD;
             (&lt;=) 7 and at least 1 of the following: persistent signs or symptoms of the ischemic&#xD;
             event at the time of randomization, or acute, ischemic brain lesion determined by&#xD;
             standard-of-care neuroimaging, or participant underwent thrombolysis or thrombectomy,&#xD;
             or transient ischemic attack (TIA): acute onset neurological deficit attributable to&#xD;
             focal ischemia of the brain by history or examination, with complete symptom&#xD;
             resolution of the deficit and no brain infarction on neuroimaging (example, computed&#xD;
             tomography (CT) scan or magnetic resonance imaging (MRI), performed as part of&#xD;
             standard medical practice), and ABCD2 Score greater than or equal to (&gt;=) 6&#xD;
&#xD;
          -  Participants will be randomized as soon as possible after determining eligibility and&#xD;
             within 48 hours of onset of event.&#xD;
&#xD;
          -  Current or planned antiplatelet treatment per international and/or local guidelines.&#xD;
             If acetyl salicylic acid (ASA) is used, it will be limited to low dose (75 to 100&#xD;
             milligrams (mg)/day). Loading dose of antiplatelet agents (including ASA) are allowed&#xD;
             per standard-of-care&#xD;
&#xD;
          -  A female participant must agree not to be pregnant, breastfeeding, or planning to&#xD;
             become pregnant until 4 days (5 half lives) after the last dose of study intervention&#xD;
&#xD;
          -  Willing and able to adhere to the lifestyle restrictions specified in this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of intracranial hemorrhage except subarachnoid hemorrhage greater than&#xD;
             (&gt;) 1 year prior with adequate treatment&#xD;
&#xD;
          -  The index stroke or TIA is considered to have a cardio-embolic etiology based on local&#xD;
             standard-of-care investigations and for which guidelines recommend anticoagulation&#xD;
&#xD;
          -  The index stroke or TIA considered to have another known cause, not related to&#xD;
             athero-thrombotic sources (treatment of acute stroke trial [TOAST] Other Determined&#xD;
             Etiology), based on local standard-of-care investigations&#xD;
&#xD;
          -  Increased risk of bleeding, including clinically significant bleeding within the&#xD;
             previous 3 months or known bleeding diathesis or known activated partial&#xD;
             thromboplastin time (aPTT) prolongation or spinal cord hemorrhage or retinal&#xD;
             hemorrhage&#xD;
&#xD;
          -  Current active liver disease, eg, acute hepatitis, known cirrhosis, including&#xD;
             participants receiving antiviral treatment for hepatitis&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to milvexian or its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>Participate-In-This-Study@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbor Ucla Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Insight Hospital and Medical Center Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Neurology Services</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Institute for Neurosciences and Multiple Sclerosis</name>
      <address>
        <city>Owosso</city>
        <state>Michigan</state>
        <zip>48867</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lincoln Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winchester Medical Center</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>Vietnam</country>
  </removed_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 19, 2023</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>May 30, 2023</last_update_submitted>
  <last_update_submitted_qc>May 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

